Jounce Therapeutics, Inc. (JNCE) |
|
1.88 0 (0%)
|
05-03 16:00 |
|
Open: |
1.92 |
Pre. Close: |
1.88 |
|
High:
|
1.93 |
Low:
|
1.88 |
|
Volume:
|
11,600,631 |
Market Cap:
|
99(M) |
|
|
|
Technical analysis |
as of: 2023-06-16 4:44:37 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 2.25  One year: 2.31 |
| Support: |
Support1: 1.84 Support2: 1.53 |
| Resistance: |
Resistance1: 1.92 Resistance2: 1.98 |
| Pivot: |
1.91 |
| Moving Average: |
MA(5): 1.89 MA(20): 1.9
MA(100): 1.33 MA(250): 2.31 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 3 %D(3): 21.5 |
| RSI: |
RSI(14): 59.5 |
| 52-week: |
High: 5.48 Low: 0.57 |
| Average Vol(K): |
3-Month: 3,097 (K) 10-Days: 1,955 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JNCE ] has closed above bottom band by 10.1%. Bollinger Bands are 81.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.88 - 1.89 |
1.89 - 1.9 |
|
Low:
|
1.85 - 1.87 |
1.87 - 1.88 |
|
Close:
|
1.86 - 1.88 |
1.88 - 1.9 |
|
Company Description |
|
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Wed, 03 May 2023
Jounce Therapeutics Announces Closing of Tender Offer - Yahoo Finance
Mon, 27 Mar 2023
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84 ... - Reuters.com
Mon, 27 Mar 2023
Jounce Therapeutics Enters Into Agreement to Be Acquired by ... - GlobeNewswire
Fri, 17 Mar 2023
Penny Stocks To Buy Now: 7 To Watch Before Next Week - Penny Stocks
Wed, 15 Mar 2023
Why Jounce Therapeutics Stock Is Moving Higher Today? - Yahoo Finance
Thu, 23 Feb 2023
Biotech firms Redx Pharma and Jounce Therapeutics to merge in ... - Reuters.com
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
53 (M) |
| Shares Float |
30 (M) |
|
% Held by Insiders
|
15.9 (%) |
|
% Held by Institutions
|
85.3 (%) |
|
Shares Short
|
2,020 (K) |
|
Shares Short P.Month
|
3,180 (K) |
Stock Financials |
|
EPS
|
-0.96 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.53 |
|
Profit Margin (%)
|
-62.1 |
|
Operating Margin (%)
|
-63.8 |
|
Return on Assets (ttm)
|
-14.1 |
|
Return on Equity (ttm)
|
-25.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.51 |
|
Sales Per Share
|
1.55 |
|
EBITDA (p.s.)
|
-0.96 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-29 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-1.96 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.53 |
|
Price to Sales
|
1.2 |
|
Price to Cash Flow
|
-3.43 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
